{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:38Z","timestamp":1786988078292,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021177","name":"Shenzhen Bay Laboratory","doi-asserted-by":"publisher","award":["21310051"],"award-info":[{"award-number":["21310051"]}],"id":[{"id":"10.13039\/501100021177","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118722","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:19:46Z","timestamp":1771949986000},"page":"118722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and synthesis of c-Met\/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC"],"prefix":"10.1016","volume":"308","author":[{"given":"Fakai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhou","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boren","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-5781","authenticated-orcid":false,"given":"Zhichao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118722_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118722_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118722_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.70043","article-title":"Breast cancer brain metastasis: bridging biological mechanisms to therapeutic innovations","volume":"4","author":"Feng","year":"2025","journal-title":"MedComm \u2013 Oncology"},{"key":"10.1016\/j.ejmech.2026.118722_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv048","article-title":"Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state","volume":"107","author":"Kohler","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2026.118722_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acs.jmedchem.3c01693","article-title":"Development of integrated bioorthogonal self-catalyzed NO donor\/platinum(IV) prodrugs for synergistical intervention against triple-negative breast cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.ejmech.2026.118722_bib7","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.2147\/OTT.S139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.118722_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acs.jmedchem.4c02642","article-title":"The potential of PARP inhibitors as antitumor drugs and the perspective of molecular design","volume":"68","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118722_bib10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJMra1407390","article-title":"Applying synthetic lethality for the selective targeting of cancer","volume":"371","author":"McLornan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118722_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yexcr.2014.08.027","article-title":"DNA single-strand break repair","volume":"329","author":"Caldecott","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2026.118722_bib12","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118722_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118722_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118722_bib16","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118722_bib17","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/bjc.2013.144","article-title":"Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers","volume":"108","author":"Lips","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118722_bib18","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118722_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118722_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118722_bib21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118722_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118722_bib23","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","article-title":"Discovery of pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118722_bib25","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118722_bib26","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2026.118722_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.breast.2016.05.014","article-title":"Surgery and radiation therapy of triple-negative breast cancers: from biology to clinics","volume":"28","author":"Bernier","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2026.118722_bib28","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","article-title":"Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of wnt\/\u03b2-catenin signaling pathway for the treatment of BRCA wild-type TNBC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib29","first-page":"455","article-title":"Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer","volume":"22","author":"Yang","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118722_bib30","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/acs.jmedchem.3c00028","article-title":"Targeting MET: discovery of small molecule inhibitors as non-small cell lung cancer therapy","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118722_bib32","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118722_bib33","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.apsb.2023.01.014","article-title":"Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118722_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14728214.2020.1791821","article-title":"Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"25","author":"Fujino","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2026.118722_bib35","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10637-020-00937-y","article-title":"Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A","volume":"38","author":"Breen","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.118722_bib36","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-14-0584","article-title":"Definition of PKC-\u03b1, CDK6, and MET as therapeutic targets in triple-negative breast cancer","volume":"74","author":"Hsu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118722_bib37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118722_bib38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.26058","article-title":"MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks","volume":"130","author":"Medov\u00e1","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118722_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers11030413","article-title":"New phosphorylation sites of Rad51 by c-Met modulates presynaptic filament stability","volume":"11","author":"Chabot","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118722_bib40","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118164","article-title":"Discovery of a novel benzofuran-7-carboxamide-based PARP1\/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance","volume":"300","author":"Sun","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib42","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib43","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1021\/acs.jmedchem.3c00821","article-title":"YCH1899, a highly effective phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib44","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016573","article-title":"Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1","volume":"296","author":"Ryan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118722_bib45","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:14:03Z","timestamp":1779743643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"alternative-id":["S0223523426001674"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118722","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of c-Met\/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118722"}}